Viagra Ingredient Launched For Pulmonary Arterial Hypertension, UK
Featured ArticleMain Category: Cardiovascular / Cardiology
Article Date: 08 Mar 2006 - 16:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate articleCurrent Article Ratings:
| Patient / Public: |  |
3.64 (11 votes) |
| Health Professional: | |
4 (3 votes) |
| Article Opinions: | 0 posts |
Revatio has been launched in the UK for the treatment of pulmonary arterial hypertension (PAH), a rare lung disorder that most commonly affects women aged 20-40. Revatio has the same active ingredient as Viagra - sildenafil.
Revatio was launched in Germany in January, 2006 and in the USA in August, 2005.
Revatio was approved in the European Union in November, 2005.
Approximately 100,000 people globally suffer from PAH.
Written by: Christian Nordqvist
Editor: Medical News Today
View drug information on Viagra.
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Cardiovascular / Cardiology headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
